Efficacy of Myopia-control Lenses in a Population of Young Adults : the OPTIMA Study
Key facts
- Who runs it
- Fondation Ophtalmologique Adolphe de Rothschild
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 134 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Essilor® Stellest® 2.0 myopia-slowing lenses
- Standard lenses
- Record updated
- 4 September 2026
Who can take part
- Age
- 16 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Spherical equivalent (SE) measured under cycloplegia using an autorefractometer, within the range 4 D ≤ SE ≤ -0.75 D for each eye
- Not currently receiving, nor having received, any preventive treatment for myopic progression in the 12 months prior to inclusion (orthokeratology, soft defocus contact lenses, low-concentration atropine eye drops, corrective spectacles with peripheral defocus)
- Myopic progression of at least -0.25 D in at least one eye during the year prior to inclusion (measurements documented by autorefractometer, with or without cycloplegia, or via previous optical prescriptions) or documented progression of axial length of +0.1 mm during the year prior to inclusion
- Primary optical correction via spectacles (occasional use of contact lenses if applicable) or agreement to wear spectacles for at least 12 hours a day, every day
- Enrolled in or a beneficiary of a social security scheme
- Signed informed consent to participate in the study by the adult patient or by a person with parental authority for minor patients
Who cannot take part
- Participation in another interventional clinical trial (drug clinical trial)
- A history of eye surgery (excluding eyelid surgery) in at least one eye
- Advanced retinal disease in at least one eye, such as myopic maculopathy
- Confirmed syndromic myopia or findings suggestive of syndromic myopia
- Obvious strabismus or significant heterophoria
- Corrected visual acuity < 8/10 in at least one eye
- Hyperopia or non-myopic astigmatism
- Anisometropia, i.e. a marked difference in correction between the two eyes
- Specific visual impairments in at least one eye requiring personalised treatments other than conventional corrective lenses
- Intolerance to optical corrections (conventional lenses or lenses with peripheral defocus)
- Patients subject to legal protection measures
- Pregnant or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 25 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if myopia-control eyeglass lenses (Essilor® Stellest® 2.0) can slow down the progression of short-sightedness (myopia) in young adults, compared with standard single-vision lenses. The main questions it aims to answer are:
Read full original descriptionShow less
Does wearing Stellest® 2.0 lenses slow the increase in eye length (axial length) after 1 year, compared with standard lenses? Does wearing Stellest® 2.0 lenses reduce the change in glasses prescription and the occurrence of eye complications after 2 years, compared with standard lenses? How well do participants tolerate the Stellest® 2.0 lenses in the first weeks of wear? Researchers will compare Stellest® 2.0 myopia-control lenses to standard single-vision lenses to see if they reduce the worsening of myopia.
Participants will:
Wear either the study glasses or standard glasses every day, at least 12 hours a day, for 2 years Attend an eye exam and vision check at the start of the study, after 1 year, and after 2 years Complete three phone check-ins during the first 3 months to report on comfort and how well they tolerate their glasses
The 2 groups in the trial
- Essilor® Stellest® 2.0 myopia-slowing lensesTreatment being tested
- standard lensesExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacité de Verres de Freination Myopique Dans Une Population de Jeunes Adultes
- Criteria questions
- Built from NCT07804043, who can take part
- Record updated
- 4 September 2026